In Reply: Tobacco Use and Trigeminal Neuralgia: Clinical Features and Outcome After Microvascular Decompression

To the Editor: We appreciate the detailed letter to the editor1 regarding our article, “Tobacco Use and Trigeminal Neuralgia: Clinical Features and Outcome After Microvascular Decompression.”2 The insights shared are valuable and contribute to an important dialogue on the impact of tobacco use in trigeminal neuralgia treatment. We acknowledge the concerns about the variability in pain assessment methods. We agree that an outcome scale like the Barrow Neurological Institute (BNI) Pain Intensity Score may have been useful to report our results in a more nuanced and standardized way; however, the outcome of pain-free off-medication (corresponding to BNI 1) is a widely used benchmark for evaluating success after trigeminal neuralgia surgery. We agree that longitudinal data about smoking habits—specifically, the timing and duration of cessation—would be helpful to obtain a full understanding of their impact on surgical outcomes. We did monitor whether smokers had quit at least 6 months before surgery, but recent discontinuation (within a month) may indeed add a component of withdrawal that could affect outcomes, which was not captured in our retrospective analysis. Likewise, we were not able to control for comorbid psychiatric conditions or other unrecorded variables that may have affected the outcome. These are all important considerations that should be examined in future work. Finally, we recognize the importance of exploring the biological mechanisms by which smoking may influence trigeminal neuralgia. The role of microvascular changes in the trigeminal nerve myelination offers a potential pathophysiologic explanation for the impact of tobacco. An investigation examining this relationship in an animal model would be useful but is outside the scope of this retrospective investigation. In summary, we concur with many of the future investigations pointed out in the letter to the editor and hope to address these in future work. The relationship between tobacco use and outcome after surgical treatment of trigeminal neuralgia is an important area of research that deserves attention.

Authors

Institutions

Publication Details

Journal
Neurosurgery
Published
2025-01-10
DOI
https://doi.org/10.1227/neu.0000000000003348
Primary Topic
Trigeminal Neuralgia and Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

In Reply: Tobacco Use and Trigeminal Neuralgia: Clinical Features and Outcome After Microvascular Decompression

Collin M. Labak, Jonathan P. Miller, Eric Herring, J. H. Shepherd et al.
Neurosurgery
Trigeminal Neuralgia and Treatments
article

In Reply: Tobacco Use and Trigeminal Neuralgia: Clinical Features and Outcome After Microvascular Decompression

Collin M. Labak, Jonathan P. Miller, Eric Herring, J. H. Shepherd, Sean Li
article en

Abstract

To the Editor: We appreciate the detailed letter to the editor1 regarding our article, “Tobacco Use and Trigeminal Neuralgia: Clinical Features and Outcome After Microvascular Decompression.”2 The insights shared are valuable and contribute to an important dialogue on the impact of tobacco use in trigeminal neuralgia treatment. We acknowledge the concerns about the variability in pain assessment methods. We agree that an outcome scale like the Barrow Neurological Institute (BNI) Pain Intensity Score may have been useful to report our results in a more nuanced and standardized way; however, the outcome of pain-free off-medication (corresponding to BNI 1) is a widely used benchmark for evaluating success after trigeminal neuralgia surgery. We agree that longitudinal data about smoking habits—specifically, the timing and duration of cessation—would be helpful to obtain a full understanding of their impact on surgical outcomes. We did monitor whether smokers had quit at least 6 months before surgery, but recent discontinuation (within a month) may indeed add a component of withdrawal that could affect outcomes, which was not captured in our retrospective analysis. Likewise, we were not able to control for comorbid psychiatric conditions or other unrecorded variables that may have affected the outcome. These are all important considerations that should be examined in future work. Finally, we recognize the importance of exploring the biological mechanisms by which smoking may influence trigeminal neuralgia. The role of microvascular changes in the trigeminal nerve myelination offers a potential pathophysiologic explanation for the impact of tobacco. An investigation examining this relationship in an animal model would be useful but is outside the scope of this retrospective investigation. In summary, we concur with many of the future investigations pointed out in the letter to the editor and hope to address these in future work. The relationship between tobacco use and outcome after surgical treatment of trigeminal neuralgia is an important area of research that deserves attention.

NeurosurgeryVol. 96(3)
The Neurological Institute (US), Case Western Reserve University (US)
Good health and well-being
Openalex Percentile: Top 99%
Trigeminal Neuralgia and Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.